Medicaid is an excellent value - $62,000 gain in quality-adjusted life years, contributing to better mental health and financial well-being. It also seems to encourage preventive screening, reveals a new study.
Researchers at Columbia University's Mailman School of Public Health analyzed the results of the Oregon Health Experiment, where eligible uninsured individuals were randomly assigned Medicaid or to stay with their current care. Study findings are online in the American Journal of Public Health
In 2008, the state of Oregon randomly provided Medicaid coverage to approximately 10,000 individuals out of 30,000 selected from all Medicaid-eligible residents. Of the 10,000 randomly receiving Medicaid there were 6,315 in the treated category and 5,769 in the control group. Using high performance computers and the resources of GRAPH, a Columbia Mailman School initiative that studies how to optimize population health policy, the researchers analyzed survey responses and biomarker data for both samples. Findings showed that Medicaid provided substantial financial protections, increased rates of preventive testing, reduced depression, and improved self-rated health. Alternately, Medicaid did not significantly lower blood pressure, serum cholesterol, or blood glucose levels.
In response to the findings, opponents of Medicaid called for its funding to be stopped, while proponents hailed the study as proof that Medicaid was a worthwhile investment because it showed some benefits. Representatives from both groups claimed that the sample size was too small to draw conclusions about physical benefits.
"Both ways of thinking are correct," said Peter Muennig, MD, MPH, associate professor of Health Policy and Management at Columbia University's Mailman School of Public Health and first author. "While the arguments of Medicaid proponents and opponents are plausible and the concerns about sample size are justified, we found that the benefits to mental health and fiscal protections are meaningful enough to justify further expansion of Medicaid."
The research team points to preventive measures like mammography and the estimates of the U.S. Task Force on Clinical Preventive Services that higher rates of screening for disease saves lives. But because there is no scientific evidence that proves this, these benefits were not included in the current analysis. "By excluding these potential benefits while including all of their costs, we can be even more certain that our estimate of $62,000 quality-adjusted life year gained is conservative," noted Muennig.
"Because none of the observed outcomes were harmful and because all costs were included, one can be much more certain that the combined effects of all benefits of Medicaid are cost-effective."